NC
ACOR

NewSquare Capital’s Acorda Therapeutics ACOR Stock Holding History

NewSquare Capital’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-25
Closed -$2K – 374
2020
Q4 		$2K Hold
25
– – ﹤0.01% 318
2020
Q3 		$2K Hold
25
– – ﹤0.01% 308
2020
Q2 		$2K Hold
25
– – ﹤0.01% 331
2020
Q1 		$3K Buy
+25
New +$4.92K ﹤0.01% 307

Other funds holding ACOR

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
CCA
Canyon Capital Advisors Dallas, Texas $772M AUM 32.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

NewSquare Capital's ACOR Position: Q1 2021 in Review

NewSquare Capital sold out of Acorda Therapeutics (ACOR) in Q1 2021, closing a stake of 25 shares — an estimated $2K sold.

NewSquare Capital first reported a position in ACOR in Q1 2020 and held it in 4 quarters. The position peaked at $3K in Q1 2020. 32 funds tracked by Wall St. Rank hold ACOR as of Q1 2021.

  • NewSquare Capital reported no remaining Acorda Therapeutics position as of Q1 2021 after selling out during the quarter.
  • NewSquare Capital sold 25 Acorda Therapeutics shares in Q1 2021, an estimated $2K.
  • NewSquare Capital first reported a position in Acorda Therapeutics in Q1 2020 and held it in 4 quarters.
  • NewSquare Capital's Acorda Therapeutics position peaked at $3K in Q1 2020.
  • 32 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2021.

Based on NewSquare Capital's 13F filing for Q1 2021, filed 10 May 2021.